Donate
Join Us

Research

Research
September 24, 2021
Taysha Gene Therapies Shares Letter to the Rett Syndrome Community
Research
September 23, 2021
Taysha Gene Therapies Announces Age Range For First Trial During Educational Rett Event for Investors
Research
September 21, 2021
A Company working on a Rett Curative Therapy is Getting Backed by a Pharmaceutical Powerhouse
Research
September 2, 2021
News from Taysha That We are One Step Closer to Testing Gene Replacement for Rett
Research
July 29, 2021
A Reason to Celebrate: Children with a Severe Neurological Disorder Improve After Gene Replacement
Research
July 10, 2021
Biopharma Tool Kit for Rett Syndrome Development Programs
Research
July 8, 2021
Gene Replacement for Rett Syndrome 101
Research
June 30, 2021
Cure 360 Webinar Series: Gene Replacement for Rett Syndrome 101
Research
June 18, 2021
Developing an Epigenetic Therapeutic for MECP2 Reactivation
Research
June 6, 2021
New Collaboration Intensifies Effort to Cure Rett Syndrome by Reactivating MECP2
Research
June 3, 2021
In their own words - members of RSRT’s newly formed Translational Medicine Advisory Board share their reasons for optimism
Research
May 26, 2021
Seven New RSRT-Supported Therapeutics Make Their Way Towards Clinical Trials
Research
May 12, 2021
Introducing ACTX 101, a Gene Therapy for Rett Using X Reactivation Technology
Research
April 26, 2021
Assessing Rett Symptoms with Cutting Edge Biosensors and Invisible Technology
Research
March 27, 2021
Taysha Gene Therapies Statement on Covid-19 Vaccines
Research
February 16, 2021
DNA Editing as a Therapeutic Modality for Rett Syndrome
Research
February 9, 2021
Novartis OAV201 Update
Research
December 16, 2020
Developing A NextGen RNA Therapy for Rett Syndrome